Summary

Global Organ Transplant Diagnostics Market: Industry Overview

In 2022, the global organ transplant diagnostics market was valued at $4.03 billion and is expected to reach $11.78 billion by 2033, with a CAGR of 10.45% during the forecast period 2023-2033. The key factors driving growth include a rise in the incidence of chronic diseases leading to organ failure increases in the use of transplant diagnostics, increase in the adoption of stem cell therapy and incidences of leukemia leading to an upsurge in demand for transplant diagnostics tests, advantages of developing advanced molecular and genomic technologies in the transplant diagnostics, and presence of favorable regulatory scenario including reimbursement schemes.

Market Lifecycle Stage

The global organ transplant diagnostics market is in the developed phase. The development of non-invasive techniques for monitoring transplant recipients using NGS and advancements in human leukocyte antigen (HLA) typing tests for an organ transplant are some of the major opportunities in the global organ transplant diagnostics market.

Impact of COVID-19

The COVID-19 pandemic impacted the healthcare segment in different ways. The organ transplant segment of the industry got highly impacted by the pandemic, as the focus of hospitals and ambulatory centers shifted toward the affected patients. Moreover, as a method of prevention, surgeries got delayed, which had a significant effect on organ transplant procedures and on organ transplant diagnostics tests.

Market Segmentation:

Segmentation 1: by Offering
• Products
• Services

The global organ transplant diagnostics market (by offering) is expected to be dominated by the services segment.

Segmentation 2: by Transplant Type
• Solid Organ Transplant
• Stem Cell Transplant

The global organ transplant diagnostics market (by transplant type) is expected to be dominated by the solid organ transplant segment.

Segmentation 3: by Application
• Diagnostics
• Translational Research

The global organ transplant diagnostics market (by application) is expected to be dominated by the diagnostics segment.

Segmentation 4: by Technology
• Molecular Technologies
• Non-Molecular Technologies
• Other Technologies

The global organ transplant diagnostics market (by technology) is expected to be dominated by the molecular technologies segment.

Segmentation 5: by End User
• Hospitals and Transplant Centers
• Academic and Research Institutions
• Reference Laboratories
• Other End Users

The global organ transplant diagnostics market (by end user) is expected to be dominated by the hospitals and transplant centers segment.

Segmentation 6: by Region
• North America - U.S., Canada
• Europe - Germany, U.K., France, Italy, Spain, Switzerland, and Rest-of-Europe
• Asia-Pacific - China, Japan, India, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific
• Latin America - Brazil, Mexico, and Rest-of-Latin America
• Rest-of-the-World

The global organ transplant diagnostics market (by region) is dominated by the North America region.

Recent Developments in the Global Organ Transplant Diagnostics Market

• In April 2023, bioMérieux S.A. and Oxford Nanopore entered into a strategic partnership agreement to develop innovative infectious disease diagnostics, which would also lead to the development of infectious disease tests used during transplantation.
• In April 2023, CareDx and Miromatrix announced an exclusive partnership to advance research using bioengineered organs for human transplantation.
• In December 2022, GenDx partnered with Azure Biosystems, a leading provider of innovative bioanalytical solutions for protein and genomic research, to demonstrate the compatibility of the Azure Cielo 6 qPCR System with the GenDx KMRtype and KMRtrack kits.
• In November 2022, Bio-Rad Laboratories and NuProbe USA signed a licensing agreement for digital PCR assay development. The technology would advance Bio-Rad’s portfolio.
• In October 2022, Eurobio Scientific finalized the purchase of a 100% stake in Genome Diagnostics BV (GenDx) in a deal valued at $132.3 million.
• In September 2022, BioMAdvanced Diagnostics announced fundraising of $1.3 million. The fundraising would allow BioMAdvanced Diagnostics to finalize the design of its first products and to start two clinical studies, one on the rejection of kidney transplants and the other on the lung.
• In September 2022, BioMAdvanced Diagnostics announced the launch of Design Freeze of its IVD test for transplant kidney rejection.
• In September 2022, GenDx announced that it signed a non-exclusive service agreement with Oxford Nanopore Technologies (Oxford Nanopore) to bring its new NGS-Turbo product to the transplant market for high-resolution HLA typing.

Demand – Drivers and Limitations

Following are the drivers for the Global Organ Transplant Diagnostics market:

• Rise in the Incidence of Chronic Diseases Leading to Organ Failure Increases the Use of Transplant Diagnostics
• Increase in the Adoption of Stem Cell Therapy and Incidences of Leukemia Leading to an Upsurge in Demand for Transplant Diagnostics Tests
• Advantages of Developing Advanced Molecular and Genomic Technologies in the Transplant Diagnostics Tests
• Presence of Favorable Regulatory Scenario Including Reimbursement Schemes

The market is expected to face some limitations as well due to the following challenges:

• Increased Gap in Organ Donation and Organ Transplant Demand, which Hinders the Growth of the Organ Transplant Diagnostics Market
• High Cost of Investment for Transplant Diagnostics Tests

How can this report add value to an organization?

Offerings: The offerings segment helps the reader understand the different manufacturers and service providers available in the market for organ transplant diagnostics. Moreover, the study provides the reader with a detailed understanding of transplant types and applications.

Growth/Marketing Strategy: The global organ transplant diagnostics market has witnessed major development by key players operating in the market, such as product launches, business expansions, partnerships, collaborations, mergers and acquisitions, funding activities, and regulatory and legal approvals. The favored strategy for the companies has been synergistic activities such as partnerships, collaborations, expansions, and funding activities. For instance, in April 2023, bioMérieux S.A. and Oxford Nanopore entered into a strategic partnership agreement to develop innovative infectious disease diagnostics, which will also lead to the development of infectious disease tests used during transplantation.

Competitive Strategy: The key players in the global organ transplant diagnostics market analyzed and profiled in the study involve established and emerging players that offer different products and services for organ transplant diagnostics. Moreover, a detailed competitive benchmarking of the players operating in the global organ transplant diagnostics market has been done to help the reader understand the ways in which players stack against each other, presenting a clear market landscape. Moreover, comprehensive competitive strategies such as partnerships, agreements, collaborations, and mergers and acquisitions will help the reader understand the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Key Companies Profiled

Manufacturers
• Abbott Laboratories
• BAG Group GmbH
• bioMérieux S.A.
• Bio-Rad Laboratories, Inc.
• Eurobio Scientific
• F. Hoffmann-La Roche Ltd.
• Illumina, Inc.
• Immucor, Inc.
• Omixon Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.

Service Providers
• ARUP Laboratories
• CareDx, Inc.
• Laboratory Corporation of America Holdings
• Quest Diagnostics Incorporated

ページTOPに戻る

Table of Contents

1 Product Definition
1.1 Inclusion and Exclusion Criteria
2 Market Scope
2.1 Scope of Work
2.2 Key Questions Answered in the Report:
3 Research Methodology
3.1 Global Organ Transplant Diagnostics Market: Research Methodology
3.2 Data Sources
3.2.1 Primary Data Sources
3.2.2 Secondary Data Sources
3.3 Market Estimation Model
3.4 Criteria for Company Profiling
4 Global Organ Transplant Diagnostics Market: Overview
4.1 Current Market Scenario
4.1.1 For Researchers
4.1.2 For Diagnostics
4.2 Market Footprint
4.3 COVID-19 Impact on Market
4.3.1 Impact on Operations
4.3.2 COVID-19 Impact: Current Scenario of Market
4.3.3 Pre- and Post-COVID-19 Impact Assessment
4.3.3.1 Pre-COVID-19 Phase
4.3.3.2 Post-COVID-19 Phase
5 Global Organ Transplant Diagnostics Market: Industry Analysis
5.1 Overview
5.2 Legal Requirements and Regulatory Frameworks in the U.S.
5.2.1 U.S. FDA Regulation
5.2.2 CMS Regulation
5.3 Legal Requirements and Framework in Europe
5.4 Legal Requirements and Framework in Asia-Pacific
5.4.1 China
5.4.2 Japan
5.5 Reimbursement Scenario
5.6 Patent Analysis
5.6.1 Patent Filing Trend (by Country)
5.6.2 Patent Filing Trend (by Year)
6 Global Organ Transplant Diagnostics Market: Market Dynamics
6.1 Impact Analysis
6.2 Market Drivers
6.2.1 Rise in Incidence of Chronic Diseases Leading to Organ Failure Increases the Use of Transplant Diagnostics
6.2.2 Increase in Adoption of Stem Cell Therapy and Incidences of Leukemia Leading to an Upsurge in Demand for Transplant Diagnostics Tests
6.2.3 Presence of Favorable Regulatory Scenarios including Reimbursement Schemes for Some Organ Transplant Diagnostics
6.2.4 Advantages of Developing Advanced Molecular and Genomic Technologies in Transplant Diagnostics Tests
6.3 Market Restraints
6.3.1 Increased Gap in Organ Donation and Organ Transplant Demand Hinders the Growth of Organ Transplant Diagnostics Market
6.3.2 High Cost of Investment for Transplant Diagnostics Tests Acts as a Barrier to Growth of the Market
6.4 Market Opportunities
6.4.1 Development of Non-Invasive Techniques for Monitoring Transplant Recipients using NGS
6.4.2 Advancements in Human Leukocyte Antigen (HLA) Typing Tests for Organ Transplant
7 Competitive Insights
7.1 Overview
7.2 Key Strategies and Development
7.2.1 Synergistic Activities
7.2.2 Product and Service Launches
7.2.3 Product Approvals
7.2.4 Acquisitions and Mergers
7.2.5 Regulatory Accreditions
7.3 Market Share Analysis 2021 vs. 2022
7.4 Growth-Share Analysis
7.4.1 By Company
8 Global Organ Transplant Diagnostics Market: (by Offering)
8.1 Overview
8.2 Products
8.2.1 Kits and Assays
8.2.2 Consumables
8.3 Services
9 Global Organ Transplant Diagnostics Market: (by Transplant Type)
9.1 Overview
9.2 Solid Organ Transplant
9.2.1 Kidney
9.2.2 Liver
9.2.3 Lung
9.2.4 Pancreas
9.2.5 Other Organs Transplant
9.3 Stem Cell Transplant
10 Global Organ Transplant Diagnostics Market: (by Application)
10.1 Overview
10.2 Diagnostics
10.2.1 Donor Testing
10.2.1.1 Pre-Transplantation Testing
10.2.1.1.1 Histocompatibility Testing
10.2.1.1.2 Blood Profiling Testing
10.2.1.1.3 Other Testing
10.2.1.2 Post-Transplantation Testing
10.2.1.2.1 Post-Infection Testing
10.2.1.2.2 Risk of Disorder Testing
10.2.1.2.3 Other Testing
10.2.2 Recipient Testing
10.2.2.1 Pre-Transplantation Testing
10.2.2.1.1 Histocompatibility Testing
10.2.2.1.2 Blood Profiling Testing
10.2.2.1.3 Other Testing
10.2.2.2 Post-Transplantation Testing
10.2.2.2.1 Post-Infection Testing
10.2.2.2.2 Risk of Disorder Testing
10.2.2.2.3 Other Testing
10.3 Translational Research
11 Global Organ Transplant Diagnostics Market: (by Technology)
11.1 Overview
11.2 Molecular Technologies
11.2.1 PCR
11.2.2 Sanger Sequencing
11.2.3 Next-Generation Sequencing (NGS)
11.2.4 Other Molecular Technologies
11.3 Non-Molecular Technologies
11.3.1 Serology
11.3.2 Flow Cytometry
11.4 Other Technologies
12 Global Organ Transplant Diagnostics Market: (by End User)
12.1 Overview
12.2 Hospitals and Transplant Centers
12.3 Academic and Research Institutions
12.4 Reference Laboratories
12.5 Other End Users
13 Region
13.1 North America
13.1.1 North America Organ Transplant Test Volume, by Transplant Type
13.1.2 Market Sizing and Forecast
13.1.2.1 North America Organ Transplant Diagnostics Market (by Country)
13.1.2.1.1 U.S.
13.1.2.1.2 Canada
13.2 Europe
13.2.1 Europe Organ Transplant Test Volume, by Transplant Type
13.2.2 Market Sizing and Forecast
13.2.2.1 Europe Organ Transplant Diagnostics Market (by Country)
13.2.2.1.1 France
13.2.2.1.2 Spain
13.2.2.1.3 U.K.
13.2.2.1.4 Italy
13.2.2.1.5 Germany
13.2.2.1.6 Switzerland
13.2.2.1.7 Rest-of-Europe
13.3 Asia-Pacific
13.3.1 Asia-Pacific Organ Transplant Test Volume, by Transplant Type
13.3.2 Market Sizing and Forecast
13.3.2.1 Asia-Pacific Organ Transplant Diagnostics Market (by Country)
13.3.2.1.1 China
13.3.2.1.2 India
13.3.2.1.3 South Korea
13.3.2.1.4 Japan
13.3.2.1.5 Australia
13.3.2.1.6 Singapore
13.3.2.1.7 Rest-of-Asia-Pacific
13.4 Latin America
13.4.1 Latin America Organ Transplant Test Volume, by Transplant Type
13.4.2 Market Sizing and Forecast
13.4.2.1 Latin America Organ Transplant Diagnostics Market (by Country)
13.4.2.1.1 Brazil
13.4.2.1.2 Mexico
13.4.2.1.3 Rest-of-Latin America
13.5 Rest-of-the-World
13.5.1 Rest-of-the-World Organ Transplant Test Volume, by Transplant Type
13.5.2 Market Sizing and Forecast
14 Company Profiles
14.1 Overview
14.2 Manufacturers
14.2.1 Abbott Laboratories
14.2.1.1 Company Overview
14.2.1.2 Role of Abbott Laboratories in the Organ Transplant Diagnostics Market
14.2.1.3 Product Portfolio
14.2.1.4 Financials
14.2.1.5 Analyst Perception
14.2.2 BAG Group GmbH
14.2.2.1 Company Overview
14.2.2.2 Role of BAG Group GmbH in the Organ Transplant Diagnostics Market
14.2.2.3 Product Portfolio
14.2.2.4 Analyst Perception
14.2.3 bioMérieux S.A.
14.2.3.1 Company Overview
14.2.3.2 Role of bioMérieux S.A. in the Organ Transplant Diagnostics Market
14.2.3.3 Product Portfolio
14.2.3.4 Financials
14.2.3.5 Recent Developments
14.2.3.6 Analyst Perception
14.2.4 Bio-Rad Laboratories, Inc.
14.2.4.1 Company Overview
14.2.4.2 Role of Bio-Rad Laboratories, Inc. in the Organ Transplant Diagnostics Market
14.2.4.3 Product Portfolio
14.2.4.4 Financials
14.2.4.5 Recent Developments
14.2.4.6 Analyst Perception
14.2.5 Eurobio Scientific (Genome Diagnostics B.V.)
14.2.5.1 Company Overview
14.2.5.2 Role of Eurobio Scientific (Genome Diagnostics B.V.) in the Organ Transplant Diagnostics Market
14.2.5.3 Product Portfolio
14.2.5.4 Analyst Perception
14.2.6 F. Hoffmann-La Roche Ltd.
14.2.6.1 Company Overview
14.2.6.2 Role of F. Hoffmann-La Roche Ltd. in the Organ Transplant Diagnostics Market
14.2.6.3 Product Portfolio
14.2.6.4 Financials
14.2.6.5 Recent Developments
14.2.6.6 Analyst Perception
14.2.7 Illumina, Inc.
14.2.7.1 Company Overview
14.2.7.2 Role of Illumina, Inc. in the Organ Transplant Diagnostics Market
14.2.7.3 Product Portfolio
14.2.7.4 Financials
14.2.7.5 Analyst Perception
14.2.8 Immucor, Inc.
14.2.8.1 Company Overview
14.2.8.2 Role of Immucor, Inc. in the Organ Transplant Diagnostics Market
14.2.8.3 Product Portfolio
14.2.8.4 Analyst Perception
14.2.9 Omixon Inc.
14.2.9.1 Company Overview
14.2.9.2 Role of Omixon Inc. in the Organ Transplant Diagnostics Market
14.2.9.3 Product Portfolio
14.2.9.4 Analyst Perception
14.2.10 QIAGEN N.V.
14.2.10.1 Company Overview
14.2.10.2 Role of QIAGEN N.V. in the Organ Transplant Diagnostics Market
14.2.10.3 Product Portfolio
14.2.10.4 Financials
14.2.10.5 Recent Developments
14.2.10.6 Analyst Perception
14.2.11 Thermo Fisher Scientific Inc.
14.2.11.1 Company Overview
14.2.11.2 Role of Thermo Fisher Scientific Inc. in the Organ Transplant Diagnostics Market
14.2.11.3 Product Portfolio
14.2.11.4 Financials
14.2.11.5 Recent Developments
14.2.11.6 Analyst Perception
14.3 Service Providers
14.3.1 ARUP Laboratories
14.3.1.1 Company Overview
14.3.1.2 Role of ARUP Laboratories in the Organ Transplant Diagnostics Market
14.3.1.3 Product Portfolio
14.3.1.4 Analyst Perception
14.3.2 CareDx, Inc.
14.3.2.1 Company Overview
14.3.2.2 Role of CareDx, Inc. in the Organ Transplant Diagnostics Market
14.3.2.3 Product Portfolio
14.3.2.4 Financials
14.3.2.5 Recent Developments
14.3.2.6 Analyst Perception
14.3.3 Laboratory Corporation of America Holdings
14.3.3.1 Company Overview
14.3.3.2 Role of Laboratory Corporation of America Holdings in the Organ Transplant Diagnostics Market
14.3.3.3 Product Portfolio
14.3.3.4 Financials
14.3.3.5 Analyst Perception
14.3.4 Quest Diagnostics Incorporated
14.3.4.1 Company Overview
14.3.4.2 Role of Quest Diagnostics Incorporated in the Organ Transplant Diagnostics Market
14.3.4.3 Product Portfolio
14.3.4.4 Financials
14.3.4.5 Analyst Perception
List of Figures
Figure 1: Global Organ Transplant Diagnostics Market, $Billion, 2022-2033
Figure 2: Global Organ Transplant Diagnostics Market, Impact Analysis
Figure 3: Global Organ Transplant Diagnostics Market (by Offering), Share (%), 2022 and 2033
Figure 4: Global Organ Transplant Diagnostics Market (by Transplant Type), Share (%), 2022 and 2033
Figure 5: Global Organ Transplant Diagnostics Market (by Application), Share (%), 2022 and 2033
Figure 6: Global Organ Transplant Diagnostics Market (by Technology), Share (%), 2022 and 2033
Figure 7: Global Organ Transplant Diagnostics Market (by End User), Share (%), 2022 and 2033
Figure 8: Global Organ Transplant Diagnostics Market (by Region), $Billion, 2022 and 2033
Figure 9: Global Organ Transplant Diagnostics Market Segmentation
Figure 10: Global Organ Transplant Diagnostics Market: Research Methodology
Figure 11: Primary Research Methodology
Figure 12: Bottom-Up Approach (Segment-Wise Analysis)
Figure 13: Top-Down Approach (Segment-Wise Analysis)
Figure 14: Global Organ Transplant Diagnostics Market, $Billion, 2022-2033
Figure 15: Global Organ Transplant Diagnostics Market, Patent Analysis (by Country), January 2018-December 2022
Figure 16: Global Organ Transplant Diagnostics Market, Patent Analysis (by Year), January 2018-December 2022
Figure 17: Global Organ Transplant Diagnostics Market, Impact Analysis
Figure 18: New Liver Cirrhosis and Other Chronic Liver Diseases Cases, Thousand, 2017 and 2021
Figure 19: Global Number of Solid Organ Transplants, 2017-2021
Figure 20: Applications of Stem Cell Therapy
Figure 21: Number of Transplants Performed and Patients on the Waiting List (by Organ), 2022
Figure 22: Global Organ Transplant Diagnostics Market, Total Number of Key Developments, January 2018-April 2023
Figure 23: Synergistic Activities, January 2018-April 2023
Figure 24: Product and Service Launches, January 2018-April 2023
Figure 25: Product Approvals, January 2018-April 2023
Figure 26: Acquisitions and Mergers, January 2018-April 2023
Figure 27: Regulatory Accreditions, January 2018-April 2023
Figure 28: Global Organ Transplant Diagnostics Market, Market Share Analysis, %, 2021 and 2022
Figure 29: Global Organ Transplant Diagnostics Market, Growth-Share Matrix (by Company), 2022
Figure 30: Global Organ Transplant Diagnostics Market (by Offering)
Figure 31: Global Organ Transplant Diagnostics Market (Products), $Billion, 2022-2033
Figure 32: Global Organ Transplant Diagnostics Market (Kits and Assays), $Million, 2022-2033
Figure 33: Global Organ Transplant Diagnostics Market (Consumables), $Million, 2022-2033
Figure 34: Global Organ Transplant Diagnostics Market (Services), $Billion, 2022-2033
Figure 35: Global Organ Transplant Diagnostics Market (by Transplant Type)
Figure 36: Global Organ Transplant Diagnostics Market (Solid Organ Transplant), $Billion, 2022-2033
Figure 37: Global Organ Transplant Diagnostics Market (Kidney), $Billion, 2022-2033
Figure 38: Global Organ Transplant Diagnostics Market (Liver), $Million, 2022-2033
Figure 39: Global Organ Transplant Diagnostics Market (Lung), $Million, 2022-2033
Figure 40: Global Organ Transplant Diagnostics Market (Pancreas), $Million, 2022-2033
Figure 41: Global Organ Transplant Diagnostics Market (Other Organs Transplant), $Million, 2022-2033
Figure 42: Global Organ Transplant Diagnostics Market (Stem Cell Transplant), $Billion, 2022-2033
Figure 43: Global Organ Transplant Diagnostics Market (by Application)
Figure 44: Global Organ Transplant Diagnostics Market (Diagnostics), $Billion, 2022-2033
Figure 45: Global Organ Transplant Diagnostics Market (Donor Testing), $Billion, 2022-2033
Figure 46: Global Organ Transplant Diagnostics Market (Pre-Transplantation Testing), $Million, 2022-2033
Figure 47: Global Organ Transplant Diagnostics Market (Histocompatibility Testing), $Million, 2022-2033
Figure 48: Global Organ Transplant Diagnostics Market (Blood Profiling Testing), $Million, 2022-2033
Figure 49: Global Organ Transplant Diagnostics Market (Other Testing), $Million, 2022-2033
Figure 50: Global Organ Transplant Diagnostics Market (Post-Transplantation Testing), $Million, 2022-2033
Figure 51: Global Organ Transplant Diagnostics Market (Post-Infection Testing), $Million, 2022-2033
Figure 52: Global Organ Transplant Diagnostics Market (Risk of Disorder Testing), $Million, 2022-2033
Figure 53: Global Organ Transplant Diagnostics Market (Other Testing), $Million, 2022-2033
Figure 54: Global Organ Transplant Diagnostics Market (Recipient Testing), $Billion, 2022-2033
Figure 55: Global Organ Transplant Diagnostics Market (Pre-Transplantation Testing), $Million, 2022-2033
Figure 56: Global Organ Transplant Diagnostics Market (Histocompatibility Testing), $Million, 2022-2033
Figure 57: Global Organ Transplant Diagnostics Market (Blood Profiling Testing), $Million, 2022-2033
Figure 58: Global Organ Transplant Diagnostics Market (Other Testing), $Million, 2022-2033
Figure 59: Global Organ Transplant Diagnostics Market (Post-Transplantation Testing), $Billion, 2022-2033
Figure 60: Global Organ Transplant Diagnostics Market (Post-Infection Testing), $Million, 2022-2033
Figure 61: Global Organ Transplant Diagnostics Market (Risk of Disorder Testing), $Million, 2022-2033
Figure 62: Global Organ Transplant Diagnostics Market (Other Testing), $Million, 2022-2033
Figure 63: Global Organ Transplant Diagnostics Market (Translational Research), $Million, 2022-2033
Figure 64: Global Organ Transplant Diagnostics Market (by Technology)
Figure 65: Global Organ Transplant Diagnostics Market (Molecular Technologies), $Billion, 2022-2033
Figure 66: Global Organ Transplant Diagnostics Market (PCR), $Million, 2022-2033
Figure 67: Global Organ Transplant Diagnostics Market (Sanger Sequencing), $Million, 2022-2033
Figure 68: Global Organ Transplant Diagnostics Market (Next-Generation Sequencing), $Million, 2022-2033
Figure 69: Global Organ Transplant Diagnostics Market (Other Molecular Technologies), $Million, 2022-2033
Figure 70: Global Organ Transplant Diagnostics Market (Non-Molecular Technologies), $Billion, 2022-2033
Figure 71: Global Organ Transplant Diagnostics Market (Serology), $Billion, 2022-2033
Figure 72: Global Organ Transplant Diagnostics Market (Flow Cytometry), $Million, 2022-2033
Figure 73: Global Organ Transplant Diagnostics Market (Other Technologies), $Million, 2022-2033
Figure 74: Global Organ Transplant Diagnostics Market (by End User)
Figure 75: Global Organ Transplant Diagnostics Market (Hospitals and Transplant Centers), $Billion, 2022-2033
Figure 76: Global Organ Transplant Diagnostics Market (Academic and Research Institutions), $Billion, 2022-2033
Figure 77: Global Organ Transplant Diagnostics Market (Reference Laboratories), $Million, 2022-2033
Figure 78: Global Organ Transplant Diagnostics Market (Other End Users), $Million, 2022-2033
Figure 79: Global Organ Transplant Diagnostics Market Share and CAGR (by Region), 2022 and 2023-2033
Figure 80: North America Organ Transplant Diagnostics Market, $Billion, 2022-2033
Figure 81: North America Organ Transplant Diagnostics Market (by Country), Share (%), 2023 and 2033
Figure 82: U.S. Organ Transplant Diagnostics Market, $Billion, 2022-2033
Figure 83: Canada Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 84: Europe Organ Transplant Diagnostics Market, $Billion, 2022-2033
Figure 85: Europe Organ Transplant Diagnostics Market (by Country), Share (%), 2022 and 2033
Figure 86: France Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 87: Spain Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 88: U.K. Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 89: Italy Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 90: Germany Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 91: Switzerland Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 92: Rest-of-Europe Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 93: Asia-Pacific Organ Transplant Diagnostics Market, $Billion, 2022-2033
Figure 94: Asia-Pacific Organ Transplant Diagnostics Market (by Country), Share (%), 2022 and 2033
Figure 95: China Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 96: India Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 97: South Korea Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 98: Japan Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 99: Australia Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 100: Singapore Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 101: Rest-of-Asia-Pacific Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 102: Latin America Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 103: Latin America Organ Transplant Diagnostics Market (by Country), Share (%), 2022 and 2033
Figure 104: Brazil Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 105: Mexico Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 106: Rest-of-Latin America Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 107: Rest-of-the-World Organ Transplant Diagnostics Market, $Million, 2022-2033
Figure 108: Total Number of Companies Profiled
Figure 109: Global Organ Transplant Diagnostics Market Overview, Key Companies
Figure 110: Abbott Laboratories: Product Portfolio
Figure 111: Abbott Laboratories: Overall Financials, $Billion, 2020-2022
Figure 112: Abbott Laboratories: Net Revenue (by Business Segment), $Billion, 2020-2022
Figure 113: Abbott Laboratories: Net Revenue (by Region), $Billion, 2020-2022
Figure 114: Abbott Laboratories: R&D Expenditure, $Billion, 2020-2022
Figure 115: BAG Group GmbH: Overall Product Portfolio
Figure 116: bioMérieux S.A.: Overall Product Portfolio
Figure 117: bioMérieux S.A.: Overall Financials, $Million, 2019-2021
Figure 118: bioMérieux S.A.: Net Revenue (by Region), $Million, 2019-2021
Figure 119: bioMérieux S.A.: R&D Expenditure, $Million, 2019-2021
Figure 120: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 121: Bio-Rad Laboratories, Inc.: Overall Financials, $Billion, 2020-2022
Figure 122: Bio-Rad Laboratories, Inc.: Net Revenue (by Business Segment), $Million, 2020-2022
Figure 123: Bio-Rad Laboratories, Inc.: Net Revenue (by Region), $Million, 2020-2022
Figure 124: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 125: Eurobio Scientific (Genome Diagnostics B.V.): Overall Product Portfolio
Figure 126: F. Hoffmann-La Roche Ltd.: Overall Product Portfolio
Figure 127: F. Hoffmann-La Roche Ltd.: Overall Financials, $Billion, 2020-2022
Figure 128: F. Hoffmann-La Roche Ltd.: Net Revenue (by Business Segment), $Billion, 2020-2022
Figure 129: F. Hoffmann-La Roche Ltd.: Diagnostics Revenue (by Region), $Billion, 2020-2022
Figure 130: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Billion, 2020-2022
Figure 131: Illumina, Inc.: Overall Product Portfolio
Figure 132: Illumina, Inc.: Overall Financials, $Million, 2020-2022
Figure 133: Illumina, Inc.: Net Revenue (by Business Segment), $Million, 2020-2022
Figure 134: Illumina, Inc.: Net Revenue (by Region), $Million, 2020-2022
Figure 135: Illumina, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 136: Immucor, Inc.: Product Portfolio
Figure 137: Omixon Inc.: Overall Product Portfolio
Figure 138: QIAGEN N.V.: Product Portfolio
Figure 139: QIAGEN N.V.: Overall Financials, $Million, 2019-2021
Figure 140: QIAGEN N.V.: Net Revenue (by Business Segment), $Million, 2019-2021
Figure 141: QIAGEN N.V.: Net Revenue (by Region), $Million, 2019-2021
Figure 142: QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021
Figure 143: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 144: Thermo Fisher Scientific Inc.: Overall Financials, $Billion, 2020-2022
Figure 145: Thermo Fisher Scientific Inc.: Net Revenue (by Business Segment), $Billion, 2020-2022
Figure 146: Thermo Fisher Scientific Inc.: Net Revenue (by Region), $Billion,2020-2022
Figure 147: Thermo Fisher Scientific Inc.: R&D Expenditure, $Billion, 2020-2022
Figure 148: ARUP Laboratories: Overall Product Portfolio
Figure 149: CareDx, Inc.: Overall Product Portfolio
Figure 150: CareDx, Inc.: Overall Financials, $Million, 2020-2022
Figure 151: CareDx, Inc.: Net Revenue (by Business Segment), $Million, 2020-2022
Figure 152: CareDx, Inc.: Net Revenue (by Region), $Million, 2020-2022
Figure 153: CareDx, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 154: Laboratory Corporation of America Holdings: Overall Product Portfolio
Figure 155: Laboratory Corporation of America Holdings: Overall Financials, $Billion, 2020-2022
Figure 156: Laboratory Corporation of America Holdings: Net Revenue (by Business Segment), $Billion, 2020-2022
Figure 157: Quest Diagnostics Incorporated: Product Portfolio
Figure 158: Quest Diagnostics Incorporated: Overall Financials, $Billion, 2020-2022
Figure 159: Quest Diagnostics Incorporated: Net Revenue (by Business Segment), $Billion, 2020-2022
List of Tables
Table 1: Key Questions Answered in the Report
Table 2: Key Coverage Providers for Organ Transplant Diagnostics Tests
Table 3: North America Organ Transplant Diagnostics Market, Impact Analysis
Table 4: North America Organ Transplant Test Volume, by Transplant Type, 2021
Table 5: Europe Organ Transplant Diagnostics Market, Impact Analysis
Table 6: Europe Organ Transplant Test Volume, by Transplant Type, 2021
Table 7: Asia-Pacific Organ Transplant Diagnostics Market, Impact Analysis
Table 8: Asia-Pacific Organ Transplant Test Volume, by Transplant Type, 2021
Table 9: Latin America Organ Transplant Diagnostics Market, Impact Analysis
Table 10: Latin America Organ Transplant Test Volume, by Transplant Type, 2021
Table 11: Rest-of-the-World Organ Transplant Diagnostics Market, Impact Analysis
Table 12: Rest-of-the-World Organ Transplant Test Volume, by Transplant Type, 2021

Press Release